Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line treatment. Although much is known about the pleiotrop...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI AG
2020-02-01
|
| Colección: | Cells |
| Materias: | |
| Acceso en línea: | https://www.mdpi.com/2073-4409/9/2/378 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|